| ×ת××××
|
Unresectable or Metastatic MelanomaYervoy (ipilimumab) is indicated for the treatment of adult patients with advanced (unresectable or metastatic) melanoma. Yervoy in combination with nivolumab is indicated for the treatment of adult and pediatric patients 12 years and older with advanced (unresectable or metastatic) melanoma . Advanced Renal Cell CarcinomaYERVOY, in combination with nivolumab, is indicated for the first-line treatment of adult patients with intermediate or poor risk, advanced renal cell carcinoma (RCC). Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal CancerYERVOY, in combination with nivolumab, is indicated for the treatment of adult and pediatric patients 12 years of age and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.Metastatic Non-Small Cell Lung CancerYERVOY, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.Hepatocellular CarcinomaYervoy, in combination with nivolumab, is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC) Child-Pugh A who have been previously treated with sorafenib.Malignant Pleural MesotheliomaYERVOY, in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesotheliomaEsophageal cancerYervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with tumour cell PD-L1 expression ⥠1%.
|
| × ×ª×× × ×ס×
|
ת×ר×× ××××× ×ס×
- 10/01/2012
|
×××××ת ×ס×
- תר××¤× ×××××ת ×ר×ש×× ×¢'× ×¨××¤× ××××× ×× ××××× ××רת
|
×ת×××× ×ס×
| ×ת×××× |
ת×ר×× ××××× |
ת××× ×§××× × |
Class Effect |
××¦× ×××× |
×ס×ס ×××××ת
|
| ×ש×××× ×¢× Nivolumab ×סר×× ×§×××רק×××× ×ר××¨×ª× ××××× ×× 12 ×©× ×× ×××¢×× ×©××× MSI-H (microsatellite instability high) ×× dMMR (mismatch repair deficient) ×שר ×××¦× ××פ×× ×§××× ×פ××××ר×פ×ר××××××, ××קס××פ×××× ×××ר×× ××ק××. |
30/01/2020 |
××× ×§×××××× |
|
MSI-H/dMMR Colorectal cancer |
|
|
×. ×תר××¤× ×ª×× ×ª× ×××פ×× ××××× ××× ××× ×תק××ת (×ר×רת×ת ×× ×©××× × × × ×ª×××) ××§× ××פ×× ×¨×ש×× ××× ××§× ××פ×× ×תק×× (×©× × ×××××)
×. ××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ×××× ×§××××××.
|
12/01/2014 |
××× ×§×××××× |
|
Melanoma |
|
| ××פ×× ×סר×× ×××× ×תק×× ×× ×ר××¨×ª× ××§× ××פ×× ×¨×ש×× ×ש×××× ×¢× Nivolumab ×××××× ××ר×ת ס×××× poor ×× intermediate. ××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×ש××ש ××פשר×××ת ×××פ×× ××פ×ר××ת ××××: Sunitinib, Sorafenib, Everolimus, Everolimus ×ש×××× ×¢× Lenvatinib, Temsirolimus, Pazopanib, Axitinib, Cabozanitinib, Nivolumab, Nivolumab ×ש×××× ×¢× Ipilimumab.
|
16/01/2019 |
××× ×§×××××× |
|
Renal cell carcinoma |
|
| ××פ×× ×סר×× ×××× ×תק×× ×× ×ר××¨×ª× ××§× ××פ×× ×¨×ש×× ×ש×××× ×¢× Nivolumab ×××××× ××ר×ת ס×××× poor ×× intermediate
|
30/01/2020 |
××× ×§×××××× |
|
Renal cell carcinoma |
|
|
×. ×תר××¤× ×ª×× ×ª× ×××פ×× ××××× ××× ××× ×תק××ת (×ר×רת×ת ×× ×©××× × × × ×ª×××) ××§× ××פ×× ×תק×× (×©× × ×××××).
×. ××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×תר××¤× ××ת ×××× ××תר×פ×ת ××פ×ר××ת ×××× â IPILIMUMAB, VEMURAFENIB.
×. ××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ×××× ×§××××××.
|
12/01/2012 |
××× ×§×××××× |
|
Melanoma |
|
| ×ש×××× ×¢× Nivolumab ×××××תרפ×× ×××פ×× ×סר×× ×¨××× ×תק×× ×× ×ר××¨×ª× ×ס×× NSCLC ××§× ××פ×× ×¨×ש××, ×××××× ×©××× × ×××××× ×××צ××ת ×ס×× EGFR, ALK, ROS1.
|
01/03/2021 |
××× ×§×××××× |
|
NSCLC, Non small cell lung cancer |
|
| 5. ×ש×××× ×¢× Nivolumab ×××פ×× ××××ת××××× ×¤×××ר××ת ×××××¨× (malignant pleural mesothelioma, MPM) ×× × ×ª×××, ××§× ××פ×× ×¨×ש××, ×¢××ר ××××× ×¢× ××ס××××××× ×ס×× non epithelioid, ×××× sarcomatoid /mixed/other.
|
03/02/2022 |
××× ×§×××××× |
|
Malignant pleural mesothelioma, MPM |
|
| ×. ×תר××¤× ×ª×× ×ª× ×××פ×× ××קר×× ××××: 1. ×××× ××× ××× ×תק××ת (×ר×רת×ת ×× ×©××× × × × ×ª×××) ××§× ××פ×× ×¨×ש×× ××× ××§× ××פ×× ×תק×× (×©× × ×××××). 2. ×ש×××× ×¢× Nivolumab ×××פ×× ××××× ××× ××× ×תק××ת (×ר×רת×ת ×× ×©××× × × ×ª×××), ×שר ××××ª× ×תק××× ×××ר ××פ×× ×§× ×¨×ש×× ×××× ×תרפ×× ×-Nivolumab ×× Pembroizumab ×× Nivolumab + Relatlimab (rechallenge). 3. ×××פ×× ×סר×× ×××× ×תק×× ×× ×ר××¨×ª× ××§× ××פ×× ×¨×ש×× ×ש×××× ×¢× Nivolumab ×××××× ××ר×ת ס×××× poor ×× intermediate. 4. ×ש×××× ×¢× Nivolumab ×סר×× ×§×××רק×××× ×ר××¨×ª× ××××× ×× 12 ×©× ×× ×××¢×× ×©××× MSI-H (microsatellite instability high) ×× dMMR (mismatch repair deficient) ×שר ×××¦× ××פ×× ×§××× ×פ××××ר×פ×ר××××××, ××קס××פ×××× ×××ר×× ××ק××. 5. ×ש×××× ×¢× Nivolumab ×××××תרפ×× ×××פ×× ×סר×× ×¨××× ×תק×× ×× ×ר××¨×ª× ×ס×× NSCLC ××§× ××פ×× ×¨×ש××, ×××××× ×©××× × ×××××× ×××צ××ת ×ס×× EGFR, ALK, ROS1. 6. ×ש×××× ×¢× Nivolumab ×××פ×× ××××ת××××× ×¤×××ר××ת ×××××¨× (malignant pleural mesothelioma, MPM) ×× × ×ª×××, ××§× ××פ×× ×¨×ש××, ×¢××ר ××××× ×¢× ××ס××××××× ×ס×× non epithelioid, ×××× sarcomatoid /mixed/other. ×. ××××× ××××ª× ×××× ××××× ×××× ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors, ×××¢× ××××× ××× ××× ×תק××ת (×ר×רת×ת ×× ×©××× × × × ×ª×××), ××ת×× ×סע××£ (×) (2) ××¢××. ×. ×תר××¤× ×ª×× ×ª× ×××פ×× ××קר×× ××××: 1. ×××× ××× ××× ×תק××ת (×ר×רת×ת ×× ×©××× × × × ×ª×××) ××§× ××פ×× ×¨×ש×× ××× ××§× ××פ×× ×תק×× (×©× × ×××××). 2. ×ש×××× ×¢× Nivolumab ×××פ×× ××××× ××× ××× ×תק××ת (×ר×רת×ת ×× ×©××× × × ×ª×××), ×שר ××××ª× ×תק××× ×××ר ××פ×× ×§× ×¨×ש×× ×××× ×תרפ×× ×-Nivolumab ×× Pembroizumab ×× Nivolumab + Relatlimab (rechallenge). 3. ×××פ×× ×סר×× ×××× ×תק×× ×× ×ר××¨×ª× ××§× ××פ×× ×¨×ש×× ×ש×××× ×¢× Nivolumab ×××××× ××ר×ת ס×××× poor ×× intermediate. 4. ×ש×××× ×¢× Nivolumab ×סר×× ×§×××רק×××× ×ר××¨×ª× ××××× ×× 12 ×©× ×× ×××¢×× ×©××× MSI-H (microsatellite instability high) ×× dMMR (mismatch repair deficient) ×שר ×××¦× ××פ×× ×§××× ×פ××××ר×פ×ר××××××, ××קס××פ×××× ×××ר×× ××ק××. 5. ×ש×××× ×¢× Nivolumab ×××××תרפ×× ×××פ×× ×סר×× ×¨××× ×תק×× ×× ×ר××¨×ª× ×ס×× NSCLC ××§× ××פ×× ×¨×ש××, ×××××× ×©××× × ×××××× ×××צ××ת ×ס×× EGFR, ALK, ROS1. 6. ×ש×××× ×¢× Nivolumab ×××פ×× ××××ת××××× ×¤×××ר××ת ×××××¨× (malignant pleural mesothelioma, MPM) ×× × ×ª×××, ××§× ××פ×× ×¨×ש××, ×¢××ר ××××× ×¢× ××ס××××××× ×ס×× non epithelioid, ×××× sarcomatoid /mixed/other.
|
17/03/2024 |
××× ×§×××××× |
|
Malignant pleural mesothelioma, MPM |
|
| ××××× ××××ª× ×××× ××××× ×××× ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors, ×××¢× ××××× ××× ××× ×תק××ת (×ר×רת×ת ×× ×©××× × × × ×ª×××), ××ת×× ×סע××£ (×) (2) ××¢××.
|
17/03/2024 |
××× ×§×××××× |
|
Malignant pleural mesothelioma, MPM |
|
|
| ש×××ש ×ס×
|
×ס×רת ××××× ×ס×
- ×. ×תר××¤× ×ª×× ×ª× ×××פ×× ××קר×× ××××:
- 1. ×××× ××× ××× ×תק××ת (×ר×רת×ת ×× ×©××× × × × ×ª×××) ××§× ××פ×× ×¨×ש×× ××× ××§× ××פ×× ×תק×× (×©× × ×××××).
- 2. ×ש×××× ×¢× Nivolumab ×××פ×× ××××× ××× ××× ×תק××ת (×ר×רת×ת ×× ×©××× × × ×ª×××), ×שר ××××ª× ×תק××× ×××ר ××פ×× ×§× ×¨×ש×× ×××× ×תרפ×× ×-Nivolumab ×× Pembroizumab ×× Nivolumab + Relatlimab (rechallenge)
- .3. ×××פ×× ×סר×× ×××× ×תק×× ×× ×ר××¨×ª× ××§× ××פ×× ×¨×ש×× ×ש×××× ×¢× Nivolumab ×××××× ××ר×ת ס×××× poor ×× intermediate.
- 4. ×ש×××× ×¢× Nivolumab ×סר×× ×§×××רק×××× ×ר××¨×ª× ××××× ×× 12 ×©× ×× ×××¢×× ×©××× MSI-H (microsatellite instability high) ×× dMMR (mismatch repair deficient) ×שר ×××¦× ××פ×× ×§××× ×פ××××ר×פ×ר××××××, ××קס××פ×××× ×××ר×× ××ק××.
- 5. ×ש×××× ×¢× Nivolumab ×××××תרפ×× ×××פ×× ×סר×× ×¨××× ×תק×× ×× ×ר××¨×ª× ×ס×× NSCLC ××§× ××פ×× ×¨×ש××, ×××××× ×©××× × ×××××× ×××צ××ת ×ס×× EGFR, ALK, ROS1.
- 6. ×ש×××× ×¢× Nivolumab ×××פ×× ××××ת××××× ×¤×××ר××ת ×××××¨× (malignant pleural mesothelioma, MPM) ×× × ×ª×××, ××§× ××פ×× ×¨×ש××, ×¢××ר ××××× ×¢× ××ס××××××× ×ס×× non epithelioid, ×××× sarcomatoid /mixed/other.
- ×. ××××× ××××ª× ×××× ××××× ×××× ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors, ×××¢× ××××× ××× ××× ×תק××ת (×ר×רת×ת ×× ×©××× × × × ×ª×××), ××ת×× ×סע××£ (×) (2) ××¢××.
- ×. ××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×××× ×§×××××× ×× ×¨××¤× ××××× ×××ר×××××× ××××¤× ×××ר×××××× ××× ×§×××××ת
|
|
